Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound tech could rival MRI for prostate cancer detection

NCT ID NCT05471128

Diagnosis Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

This study compares two methods for detecting serious prostate cancer: MRI fusion biopsy and micro-ultrasound (ExactVu). Researchers want to see if micro-ultrasound can find dangerous cancers as well as MRI, and if it can be used in communities with limited healthcare access. The study involves 29 men scheduled for biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that micro-ultrasound is a reliable, more accessible alternative to MRI for detecting serious prostate cancer.
What could go wrong
This is a small, early-stage study with only 29 participants, so results may not apply to everyone. The technology may not be as accurate as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

29 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will cover all races, including socioeconomically disadvantaged minorities, that have been diagnosed with prostate cancer.

Ages

18 to 99 years

Sex

Male participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients scheduled to undergo biopsy and with one of the following: * Men with suspicion of prostate cancer * Men on active surveillance 2. Age ≥18 \[30\] 3. Have available multiparametric prostate MRI 4. Able to provide written, informed consent 5. No significant medical illness which in the opinion of the Investigator would preclude entry to study procedures 6. Be willing and able to comply with scheduled visits Exclusion Criteria: 1. Previously confirmed prostate cancer diagnosis with Grade Group \>= 2 2. Unable to undergo prostate biopsy 3. Prostate MRI unable to be evaluated using the PI-RADS v2 criteria 4. Men with contraindication for MRI or a prostate biopsy 5. Prostate biopsy within 8 weeks prior to mpMRI. 6. Any history of prostate treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.